Ampersand Capital acquires Purna Pharmaceuticals
Wednesday, March 4, 2026 · first reported by Pharmaceutical Business review -
Ampersand Capital acquired Purna Pharmaceuticals in healthcare expansion. Transaction shows continued deployment in pharma/biotech sector consistent with firm's healthcare focus.
- Also named
- Purna Pharmaceuticals
- Asset class
- Private equity
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
Coverage
1 source- Antin agrees sale of majority stake in Vicinity Energy to Harrison StreetPrivate Equity Wire +3
- CPP Investments sells A$4.5bn Australian toll road stakes to TransurbanIPE Real Assets
- Sycamore nears $9bn sale of Boots to Weston familyPrivate Equity Wire
- Eagle Point backs $450m US government-leased real estate recapitalisationIPE Real Assets
- CSC acquires 50% Watergardens mall stake from QIC for A$480mIPE Real Assets
- Lone Star buys €216m Dutch residential portfolio from Catella fundIPE Real Assets